ephrin-a5 has been researched along with Cancer of Prostate in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Cai, C; Guo, Y; Lan, T; Li, S; Liu, L; Ma, P; Xu, Y; Zhang, H; Zhang, M | 1 |
Chen, Y; Guan, M; He, P; Kang, Z; Li, S; Ma, P; Ma, X; Wang, H; Wu, Z; Xu, X; Xu, Y; Yin, L; Zhang, X; Zhao, Y | 1 |
Aebersold, R; Cerny, T; Cima, I; Fankhauser, N; Gillessen, S; Kälin, M; Krek, W; Powles, T; Schiess, R; Templeton, A; Wild, P | 1 |
3 other study(ies) available for ephrin-a5 and Cancer of Prostate
Article | Year |
---|---|
ADAM10-cleaved ephrin-A5 contributes to prostate cancer metastasis.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Ephrin-A5; Humans; Ligands; Male; Membrane Proteins; Mice; Mice, Nude; Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Down-Regulation; Ephrin-A5; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, EphA7; Signal Transduction; Tumor Suppressor Proteins | 2017 |
Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the pten conditional knockout mouse proteome.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; C-Reactive Protein; Cell Adhesion Molecules; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Ephrin-A5; Humans; Kaplan-Meier Estimate; Male; Mass Spectrometry; Mice; Mice, Knockout; Middle Aged; Nectins; Neprilysin; Nomograms; Predictive Value of Tests; Prostatic Neoplasms; Proteomics; PTEN Phosphohydrolase; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Switzerland; Thrombospondin 1; Time Factors; Treatment Failure | 2011 |